Recursion Q3: Revenue Beat, $561.5M Cash, Tempus Deal Restructured, Controls Still Weak
RXRX sits 38% above its 52-week low of $2.77.
Summary
Recursion's Q3 10-Q confirms the revenue beat and shows $561.5 million of cash after a $264.5 million nine-month burn, with the October offering adding $187.2 million net. The filing also details a restructured Tempus data deal and confirms Exscientia-related material weaknesses remain unremediated.
Key Events · Earnings and Guidance · RXRX
-
Q3 Revenue Jumps on Sanofi Milestone
Total revenue was $18.552 million versus $5.175 million a year ago, driven by a $10.0 million Sanofi immunology development-candidate milestone; net loss narrowed to $119.036 million from $162.253 million.
-
Cash Falls but Burn Slows
Cash, equivalents and restricted cash totaled $561.5 million at September 30, 2026, down from $753.9 million at December 31, 2025; nine-month operating cash use was $264.5 million versus $325.7 million a year earlier.
-
October Offering Adds $187.2M Net
The company completed the sale of 61.5 million Class A shares on October 16, 2026 for net proceeds of approximately $187.2 million; the TD Cowen ATM still has $213.3 million available after $85.5 million of net sales in the first nine months.
-
Tempus Deal Rewritten, Fees Cut
The September 15, 2026 amendment extends the Tempus data agreement to six years and removes termination for convenience, while cutting annual license fees to $14.0 million for years three through five, with at least $4.0 million payable in cash and the balance payable in stock or cash at Recursion's election.
Analysis · RXRX · Life Sciences
The headline numbers were already out via the same-day 8-K, but the 10-Q is where the balance sheet and the fine print land. Cash and restricted cash fell to $561.5 million from $753.9 million at year-end, and the company burned $264.5 million on operations in nine months — a slower burn than the $325.7 million a year ago, helped by R&D down 18% and G&A down 22%. The October offering added $187.2 million net, which is what actually pushes runway past the twelve-month minimum the filing itself commits to. Two items deserve attention beyond the P&L: Recursion rewrote its Tempus data deal, extending the term to six years and giving up its right to walk away, in exchange for cutting the annual fee to $14.0 million for years three through five (at least $4.0 million in cash, the rest payable in stock at Recursion's election) — a real cash-cost saving but a new source of share issuance. And management again concluded disclosure controls were ineffective because the Exscientia-era material weaknesses are not yet remediated, which keeps a governance overhang in place.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXRX was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.